Growth Metrics

Gyre Therapeutics (GYRE) Short term Debt (2016)

Gyre Therapeutics has reported Short term Debt over the past 7 years, most recently at $28000.0 for Q3 2016.

  • Quarterly Short term Debt fell 95.86% to $28000.0 in Q3 2016 from the year-ago period, while the trailing twelve-month figure was $28000.0 through Sep 2016, down 95.86% year-over-year, with the annual reading at $1.2 million for FY2015, N/A changed from the prior year.
  • Short term Debt was $28000.0 for Q3 2016 at Gyre Therapeutics, down from $130000.0 in the prior quarter.
  • Over five years, Short term Debt peaked at $1.2 million in Q4 2015 and troughed at $28000.0 in Q3 2016.
  • The 5-year median for Short term Debt is $847500.0 (2012), against an average of $690625.0.
  • Year-over-year, Short term Debt skyrocketed 41.42% in 2015 and then crashed 95.86% in 2016.
  • A 5-year view of Short term Debt shows it stood at $851000.0 in 2012, then rose by 0.24% to $853000.0 in 2013, then plummeted by 43.96% to $478000.0 in 2014, then soared by 141.84% to $1.2 million in 2015, then crashed by 97.58% to $28000.0 in 2016.
  • Per Business Quant, the three most recent readings for GYRE's Short term Debt are $28000.0 (Q3 2016), $130000.0 (Q2 2016), and $196000.0 (Q1 2016).